276 related articles for article (PubMed ID: 34135266)
1. Development of outcome measures according to dystrophic phenotypes in canine X-linked muscular dystrophy in Japan.
Kuraoka M; Aoki Y; Takeda S
Exp Anim; 2021 Nov; 70(4):419-430. PubMed ID: 34135266
[TBL] [Abstract][Full Text] [Related]
2. Accelerometric outcomes of motor function related to clinical evaluations and muscle involvement in dystrophic dogs.
Kuraoka M; Nitahara-Kasahara Y; Tachimori H; Kato N; Shibasaki H; Shin A; Aoki Y; Kimura E; Takeda S
PLoS One; 2018; 13(12):e0208415. PubMed ID: 30533017
[TBL] [Abstract][Full Text] [Related]
3. Serum Osteopontin as a Novel Biomarker for Muscle Regeneration in Duchenne Muscular Dystrophy.
Kuraoka M; Kimura E; Nagata T; Okada T; Aoki Y; Tachimori H; Yonemoto N; Imamura M; Takeda S
Am J Pathol; 2016 May; 186(5):1302-12. PubMed ID: 26963343
[TBL] [Abstract][Full Text] [Related]
4. Dystrophin deficiency in canine X-linked muscular dystrophy in Japan (CXMDJ) alters myosin heavy chain expression profiles in the diaphragm more markedly than in the tibialis cranialis muscle.
Yuasa K; Nakamura A; Hijikata T; Takeda S
BMC Musculoskelet Disord; 2008 Jan; 9():1. PubMed ID: 18182116
[TBL] [Abstract][Full Text] [Related]
5. Major clinical and histopathological characteristics of canine X-linked muscular dystrophy in Japan, CXMDJ.
Shimatsu Y; Yoshimura M; Yuasa K; Urasawa N; Tomohiro M; Nakura M; Tanigawa M; Nakamura A; Takeda S
Acta Myol; 2005 Oct; 24(2):145-54. PubMed ID: 16550932
[TBL] [Abstract][Full Text] [Related]
6. Activation and localization of matrix metalloproteinase-2 and -9 in the skeletal muscle of the muscular dystrophy dog (CXMDJ).
Fukushima K; Nakamura A; Ueda H; Yuasa K; Yoshida K; Takeda S; Ikeda S
BMC Musculoskelet Disord; 2007 Jun; 8():54. PubMed ID: 17598883
[TBL] [Abstract][Full Text] [Related]
7. Motor physical therapy affects muscle collagen type I and decreases gait speed in dystrophin-deficient dogs.
Gaiad TP; Araujo KP; Serrão JC; Miglino MA; Ambrósio CE
PLoS One; 2014; 9(4):e93500. PubMed ID: 24713872
[TBL] [Abstract][Full Text] [Related]
8. Cardiac involvement in Beagle-based canine X-linked muscular dystrophy in Japan (CXMDJ): electrocardiographic, echocardiographic, and morphologic studies.
Yugeta N; Urasawa N; Fujii Y; Yoshimura M; Yuasa K; Wada MR; Nakura M; Shimatsu Y; Tomohiro M; Takahashi A; Machida N; Wakao Y; Nakamura A; Takeda S
BMC Cardiovasc Disord; 2006 Dec; 6():47. PubMed ID: 17140458
[TBL] [Abstract][Full Text] [Related]
9. Repression of phosphatidylinositol transfer protein α ameliorates the pathology of Duchenne muscular dystrophy.
Vieira NM; Spinazzola JM; Alexander MS; Moreira YB; Kawahara G; Gibbs DE; Mead LC; Verjovski-Almeida S; Zatz M; Kunkel LM
Proc Natl Acad Sci U S A; 2017 Jun; 114(23):6080-6085. PubMed ID: 28533404
[TBL] [Abstract][Full Text] [Related]
10. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide association study to identify potential genetic modifiers in a canine model for Duchenne muscular dystrophy.
Brinkmeyer-Langford C; Balog-Alvarez C; Cai JJ; Davis BW; Kornegay JN
BMC Genomics; 2016 Aug; 17(1):665. PubMed ID: 27549615
[TBL] [Abstract][Full Text] [Related]
12. Determination of qPCR Reference Genes Suitable for Normalizing Gene Expression in a Canine Model of Duchenne Muscular Dystrophy.
Hildyard JCW; Taylor-Brown F; Massey C; Wells DJ; Piercy RJ
J Neuromuscul Dis; 2018; 5(2):177-191. PubMed ID: 29614692
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for Duchenne muscular dystrophy: myonecrosis, inflammation and oxidative stress.
Grounds MD; Terrill JR; Al-Mshhdani BA; Duong MN; Radley-Crabb HG; Arthur PG
Dis Model Mech; 2020 Mar; 13(2):. PubMed ID: 32224496
[TBL] [Abstract][Full Text] [Related]
14. Long-term functional adeno-associated virus-microdystrophin expression in the dystrophic CXMDj dog.
Koo T; Okada T; Athanasopoulos T; Foster H; Takeda S; Dickson G
J Gene Med; 2011 Sep; 13(9):497-506. PubMed ID: 22144143
[TBL] [Abstract][Full Text] [Related]
15. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
16. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD).
Nadarajah VD; van Putten M; Chaouch A; Garrood P; Straub V; Lochmüller H; Ginjaar HB; Aartsma-Rus AM; van Ommen GJ; den Dunnen JT; 't Hoen PA
Neuromuscul Disord; 2011 Aug; 21(8):569-78. PubMed ID: 21724396
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Multi-exon Skipping Treatment in Duchenne Muscular Dystrophy Dog Model Neonates.
Lim KRQ; Echigoya Y; Nagata T; Kuraoka M; Kobayashi M; Aoki Y; Partridge T; Maruyama R; Takeda S; Yokota T
Mol Ther; 2019 Jan; 27(1):76-86. PubMed ID: 30448197
[TBL] [Abstract][Full Text] [Related]
18. Predictive markers of clinical outcome in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Pinto-Mariz F; Yada E; Desquilbet L; Savino W; Silva-Barbosa SD; Faussat AM; Mouly V; Voit T; Blot S; Butler-Browne G
Dis Model Mech; 2014 Nov; 7(11):1253-61. PubMed ID: 25261568
[TBL] [Abstract][Full Text] [Related]
19. Effects of an immunosuppressive treatment in the GRMD dog model of Duchenne muscular dystrophy.
Barthélémy I; Uriarte A; Drougard C; Unterfinger Y; Thibaud JL; Blot S
PLoS One; 2012; 7(11):e48478. PubMed ID: 23185260
[TBL] [Abstract][Full Text] [Related]
20. Quantitative phenotyping of Duchenne muscular dystrophy dogs by comprehensive gait analysis and overnight activity monitoring.
Shin JH; Greer B; Hakim CH; Zhou Z; Chung YC; Duan Y; He Z; Duan D
PLoS One; 2013; 8(3):e59875. PubMed ID: 23544107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
